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To the Editor, 
Acrodermatitis enteropathica (AE; MIM# 201100) is a rare autosomal recessive disorder 
characterised by zinc deficiency due to a defect of zinc absorption through the intestine
1
. 
Acral dermatitis, diarrhoea and alopecia form the classical triad of AE although the clinical 
features may vary from one patient to another
2,3
. The normal level of zinc in blood is around 
160ug/dL but drops to <50ug/dL in patients with AE which can lead to an impairment of the 
immune system and increase the possibility of infections and eye problems. If not treated, 
AE can even progress to multiple organ failure and death. AE is caused by mutations in the 
SLC39A4 gene located in the 8q24.3 chromosomal region.  SLC39A4 encodes ZIP4, a 68kDa 
zinc transporter protein highly expressed in the duodenum and jejunum which are the main 
sites for zinc uptake
4
. Zip4 knockout mice develop systemic zinc deficiency and loss of 
intestinal integrity
5
.  There are at least 40 mutations identified in the SLC39A4 gene so far 
that have been associated with AE. These mutations are spread along all 12 exons and 
include missense and nonsense mutations, small and large deletions or insertions causing 
frame-shifts, and splice-site substitutions
6
.  A three generation family from the region of 
Tabuk in the north-western region of Saudi Arabia has two patients with AE (B03 and B06) 
Figure 1. In this family AE patients had a severe clinical phenotype. The first patient was a 30 
year old Saudi male. He presented with painful oral ulceration and a pustular skin eruption 
affecting the face, scalp, chest, legs and feet. He had a very low plasma zinc level <26 ug/dL 
(normal: 60-120 ug/dL). He had been on oral zinc supplements since childhood and, on 
several occasions, the mouth ulceration and skin lesions had recurred during periods when 
he had stopped taking his regular dosage of zinc. The second patient was a female. She was 
five months old when she presented the first clinical features. These were similar to her 
older brother (see above). Both patients respond perfectly to the treatment with symptoms 
gradually disappearing after starting take daily zinc supplements.  
DNA samples from 11 individuals from this AE family were amplified by PCR after 
optimisation of PCR conditions. Primers and PCR conditions for each amplicon are as 
described in on-line supplemental materials. 15 kb of chromosome region 8q24.3, including 
the 12 exons of SLC39A4 were sequenced in the 11 individuals. Note that there are two 
mRNA variants of SLC39A (variant 1 NM_130849.3 and variant 2 NM_017767.2) which differ 
ŝŶƚŚĞŝƌ  ? ?ƌĞŐŝŽŶ ?Therefore primers were designed to cover the regions encoding for both 
variants (Figure 1Sup; on-line supplemental materials).  Sequence alignments using the 
generated sequence data of SLC39A in the 11 family members were performed (Figure 
2Sup; on-line supplemental materials). The sequences were aligned by amplicon from all 
samples plus SLC39A reference sequence (accession number NM_130849.3). The SLC39A 
coding sequence was re-sequenced in another laboratory to confirm the results of the first 
round of sequencing. 
Sequence alignments revealed several SNPs including synonymous and non-synonymous 
substitutions (Figure 2Sup; on-line supplemental materials). We focused on non-
synonymous substitutions which gave rise to amino acid changes, of which there were five 
identified in these individuals (Table 1). None of these variations seems to segregate with 
disease phenotype except for one which gives a change from the neutral aliphatic amino 
acid (glycine) to the highly hydrophobic aromatic amino acid (tryptophan) at position 
p.Gly512Trp (c.1534G>T), with the genotype c.1534G>T showing perfect segregation with 
the AE phenotype in our family and appearing in homozygous state in the two affected 
members B03 and B06 (Table 1 and Figure 1).  Our findings have been confirmed by 
bioinformatics analysis using MutationTaster at www.mutationtaster.org. MutationTaster 
calculates probabilities for the alteration to be either a disease mutation or a harmless 
polymorphism. The prediction is based on the frequencies of all single features for known 
disease mutations/polymorphisms available in databases such as HGMD Professional and 
the 1000 Genomes Project. These were used as a root to calculate the probability for the 
alteration SLC39A4 G to T transversion at position 1534 (for sequence accession number 
NM_130849). The prediction gave a high score with probability of 0.99999 predicting that 
the SLC39A4 mutation G1534T is a disease causing mutation. In addition, the conservation 
of glycine at position 512 of human ZIP4 in different species including mammalians, birds 
and fish indicate the importance of this amino acid in ZIP4 function (Figure 3Sup; on-line 
supplemental materials). Amino acids surrounding G512 are also conserved suggesting that 
this region of ZIP4 is under negative selection pressure, which allows this domain to 
preserve its function (Figure 3Sup; on-line supplemental materials).                                                                           
Attempts to correlate genotype and phenotype of AE patients were possibly not successful 
because of the lack of a large data set including molecular and clinical data. However, Smith 
and colleagues also found no clinical difference between 35 AE patients carrying different 
SLC39A4 mutations
6
. Our AE patients present similar clinical features to those previously 
described in the literature but unlike AE patients heterozygous for certain SLC39A4 
mutations (eg c1223_1227delCCGGG) the heterozygous members of our Saudi family were 
asymptomatic. One of the patients in the Saudi family has been admitted to hospital 
emergency services after omitting taking zinc supplement tablets for just a couple of days, 
suggesting that the SLC39A4 mutation G1640T might have caused a complete loss of ZIP4 
function. The p.Gly512Trp (c.1534G>T) mutation is located within highly-conserved amino 
acids sequence ADG512LA (Figure 2Sup) which corresponds to the fourth putative 
transmembrane domain of ZIP4
6
. This mutation has also been reported in two AE families 
from North Africa
6
 but it has not so far been identified in families originating outside North 
Africa and the Middle East, suggesting the mutation originated in this part of the world. 
There is strong link between populations in North Africa and Middle East. In fact, during the 
seventh century the Arabs invaded North Africa and it could be hypothesised that 
p.Gly512Trp first appeared in the Middle East and has been spread in North Africa during 
Arab invasions
8
but this hypothesis needs to be tested.    
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